Search

EHA-SWG Scientific Meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis

Dates: February 8-10, 2018 
Location: Barcelona, Spain
Chair: MC Béné
Co-chair: G Zini

Organized by: EHA & the EHA Scientific Working Group on Diagnosis: Morphology and Flow Cytometry

After a successful first edition in 2015, this meeting returns to Barcelona on February 8-10, 2018.…

Read more

For mentors

When discussing this career development opportunity with your associates, please keep in mind that applicants with the same mentor are eligible to apply. However, no more than ONE participant from a specific mentor will be selected.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

EHA supports the proposal for a Regulation on the European Health Data Space (EHDS)

On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.

Read more

EHA and Polish Society’s third tutorial together focused on myeloid and lymphoid leukemias

Seventy-five participants from Europe and the Middle East learned about the advances in biology, genetic characteristics, diagnostic approaches and therapy of leukemias during the EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias in Warsaw, Poland.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

The European Parliament adopts the Regulation on Substances of Human Origins (SoHO)

On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).

Read more

EU calls for proposal 2023

IntroductionHorizon Europe is the research and innovation programme of the EU for the period 2021-2027. The programme facilitates research collaboration and strengthens the impact of R&I in developing, supporting and implementing EU policies while tackling global challenges.

Read more